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Staphylococcus aureus is a Gram-positive pathogen that causes a diverse range of bacterial infections. Invasive S. aureus strains
secrete an extensive arsenal of hemolysins, immunomodulators, and exoenzymes to cause disease. Our studies have focused on
the secreted enzyme hyaluronidase (HysA), which cleaves the hyaluronic acid polymer at the -1,4 glycosidic bond. In the study
described in this report, we have investigated the regulation and contribution of this enzyme to S. aureus pathogenesis. Using
the Nebraska Transposon Mutant Library (NTML), we identified eight insertions that modulate extracellular levels of HysA ac-
tivity. Insertions in the sigB operon, as well as in genes encoding the global regulators SarA and CodY, significantly increased
HysA protein levels and activity. By altering the availability of branched-chain amino acids, we further demonstrated CodY-de-
pendent repression of HysA activity. Additionally, through mutation of the CodY binding box upstream of hysA, the repression
of HysA production was lost, suggesting that CodY is a direct repressor of hysA expression. To determine whether HysA is a viru-
lence factor, a hysA mutant of a community-associated methicillin-resistant S. aureus (CA-MRSA) USA300 strain was con-
structed and found to be attenuated in a neutropenic, murine model of pulmonary infection. Mice infected with this mutant
strain exhibited a 4-log-unit reduction in bacterial burden in their lungs, as well as reduced lung pathology and increased levels
of pulmonary hyaluronic acid, compared to mice infected with the wild-type, parent strain. Taken together, these results indicate
that S. aureus hyaluronidase is a CodY-regulated virulence factor.
Staphylococcus aureus is a leading cause of both hospital andcommunity-associated infections in the developed world, ac-
counting for $14.5 billion in health care costs annually in the
United States alone (1). These infections range from mild skin and
soft tissue infections to potentially fatal infections, such as pneu-
monia, endocarditis, osteomyelitis, sepsis, and toxic shock syn-
drome (2). Additionally, the increasing prevalence of methicillin-
resistant S. aureus (MRSA) strains in both the hospital and
community has exacerbated the problem (3–5). S. aureus is a suc-
cessful pathogen due to its extensive arsenal of virulence factors
that consist of both surface-associated proteins, such as microbial
surface components recognizing adhesive matrix molecules
(MSCRAMMs), and secreted proteins, including hemolysins, im-
munomodulators, and a number of exoenzymes (2, 3). Many
emerging MRSA isolates are known for causing tissue-destructive
infections (5, 6), and it has been proposed that the excessive dam-
age is due, in part, to the large quantities of toxins and secreted
enzymes produced by these new isolates (7).
Our studies have focused on the exoenzyme hyaluronidase
(also called hyaluronate lyase), encoded by the gene hysA (8). Hya-
luronidases are bacterial enzymes that cleave the -1,4 glycosidic
bond of hyaluronic acid (HA), a high-molecular-weight polymer
composed of repeating disaccharide units of N-acetylglucosamine
and D-glucuronic acid (9, 10). Hyaluronic acid is synthesized and
secreted from the plasma membrane of mammalian cells, and it is
abundant in the skin, skeletal tissue, umbilical cord, lungs, heart
valves, brain, and a number of other tissues (9–11). Hyaluronic
acid also performs a multitude of functions for the host, including
providing structure to tissues and water homeostasis, assisting
with cell proliferation, and acting as an immune regulator (10,
11). Many of these tissues with high HA concentrations are fre-
quently infected with S. aureus (2).
Cleavage of HA by bacterial hyaluronidases occurs by  elim-
ination of the -1,4 glycosidic bond and results in unsaturated
disaccharides as the product of complete digestion (9). In con-
trast, the eukaryotic hyaluronidases hydrolyze the -1,4 glycosidic
bond, producing mostly tetra- and hexasaccharides as end prod-
ucts. For a number of Gram-positive organisms, hyaluronidases
have been shown to be essential virulence factors because of their
ability to disseminate cells and virulence factors through tissue
(9). For example, -toxin, a hyaluronidase of Clostridium perfrin-
gens, was found to significantly increase the ability of -toxin to
penetrate tissue (12). Similarly, a mutant with a mutation in the
hyaluronidase of Streptococcus pyogenes showed reduced tissue
penetration compared to the wild type in a murine skin abscess
model (13). Additionally, there have been a number of structural
studies on the hyaluronidases from Streptococcus pneumoniae and
Streptococcus agalactiae (14–16), and the S. aureus enzyme is re-
ported to have a structure similar to the structures of these strep-
tococcal enzymes (9).
Reports of S. aureus hyaluronidase date back to pioneering
1933 studies performed by Duran-Reynals (17), who identified a
spreading factor found in the spent medium of invasive S. aureus
strains. This spreading factor increased the lesion size in a rabbit
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skin infection model, as measured by the spread of India ink (17),
and it could increase the size of lesions caused by other bacterial
pathogens. Subsequent reports concluded that the enzyme hyal-
uronidase was responsible for the spreading factor activity (18–
21), but Hobby et al. suggested that other agents may contribute to
the phenomenon (22). A number of follow-up studies investi-
gated the enzymatic properties and expression of S. aureus hyal-
uronidase (23–25), but in the intervening years, progress stag-
nated until the hysA gene was identified and sequenced (26). More
recently, the HysA enzyme was detected in proteomic studies (27)
and shown to be required for increased wound size in a murine
skin infection model (28). Little is known about hysA regulation,
although SarA is thought to repress hysA gene expression, and
there is some evidence that the agr quorum-sensing system in-
duces expression (28, 29).
To expand our knowledge of HysA in S. aureus, we proceeded
to investigate the regulation and the contribution of this enzyme
to pathogenicity. We identified genes involved in the regulation of
hysA utilizing a transposon mutant library, and the most promi-
nent of these was the global regulator CodY. We characterized the
role of HysA in the pathogenesis of S. aureus using a murine pul-
monary infection model, and we present evidence that HysA pro-
motes virulence through the breakdown of hyaluronic acid during
infection.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. The bacterial strains
and plasmids used in this study are described in Table 1. All S. aureus
strains were grown in tryptic soy broth (TSB) or tryptic soy agar (TSA)
with the appropriate antibiotics for plasmid maintenance or selection
(ampicillin, 100 g/ml; chloramphenicol, 10 g/ml; erythromycin, 10
g/ml; tetracycline, 0.625 g/ml) at 37°C with shaking at 220 rpm with a
flask-to-volume ratio of approximately 5:1, unless otherwise specified.
Hyaluronic acid sodium salt purified from Streptococcus equi was pur-
chased from Sigma-Aldrich. Plasmid DNA was purified from Escherichia
coli and electroporated into S. aureus RN4220 as previously described
(30). Plasmids and transposon insertions were moved from S. aureus
RN4220 or S. aureus JE2 with bacteriophage 11 to other S. aureus strains
by transduction. All of the oligonucleotides used for this study can be
found in Table 2.
The hysA mutant was constructed using the pJB38-hysA modified
pKOR1 system as described previously (31). Briefly, 600-bp flanking re-
gions upstream and downstream of hysA were amplified and joined by
overlap PCR extension using genomic DNA from strain AH1263 as the
template and oligonucleotides CBR12 and CBR13 to generate the up-
stream fragment and oligonucleotides CBR14 and CBR15 to generate the
downstream fragment. The outermost primers (CBR12 and CBR15) were
engineered to include SbfI and XmaI sites at their 5= ends, respectively,
and the inner primers (CBR13 and CBR14) were similarly engineered
with XhoI and MluI sites at their 5= ends to aid with the overlap extension.
PCR products were ligated with T4 DNA ligase (Invitrogen) into pJB38 at
the SbfI and XmaI sites and electroporated into E. coli strain BW25141.
Plasmid DNA was purified from this strain, isolated using a high-speed
plasmid minikit (IBI Scientific), and electroporated into RN4220. The
plasmid construct was isolated from S. aureus RN4220 and transduced
into AH1263 using bacteriophage 11. The hysA mutation was con-
structed on the chromosome as previously outlined in the pJB38 method
(31). The final colonies were screened for plasmid loss by determination
of antibiotic susceptibility, and loss of the plasmid was confirmed by PCR.
The complementing plasmid pHysA (pCR01) was created by ampli-
fying the hysA promoter region (600 bp upstream of the putative trans-
lational start site) through the stop codon with the flanking primers
CBR35 and CBR29. Amplified DNA containing the hysA coding sequence
and the promoter region was restriction digested with BamHI-HF and
NheI-HF (New England BioLabs) and ligated into linearized pSKerm-
MCS plasmid DNA at the BamHI and NheI sites. Ligated DNA was elec-
troporated into E. coli strain BW25141 using standard molecular tech-
niques.
To create the HysA overexpression construct pCR03, the hysA gene
without the encoded signal sequence was amplified from AH1263
genomic DNA using primers CBR41 and CBR42, which contain NheI and
TABLE 1 Strains and plasmids





BW25141 Cloning strain 58
ER2566 Protein expression strain New England
Biolabs
DH5 Cloning/protein expression strain Gibco




RN4220 Restriction-deficient strain 8325-4 59
AH1263 USA300 CA-MRSA Erms (LAC) 39
AH2525 AH1263 hysA This work
AH2839 AH2525 containing pHysA This work
JE2 CA-MRSA USA300 Erms, plasmid-
cured LAC derivative
40
AH2914 JE2 hysA::	 Ermr 40
AH2936 JE2 sarA::	 Ermr 40
AH2937 JE2 sigB::	 Ermr 40
AH2938 JE2 rsbW::	 Ermr 40
AH2939 JE2 rsbU::	 Ermr 40
AH2942 JE2 SAUSA300_0543::	 Ermr 40
AH2945 JE2 hslU::	 Ermr 40
AH2946 JE2 codY::	 Ermr 40
AH3052 AH1263 spa This work
AH3134 AH1263 spa codY::	 Ermr This work
AH3207 AH1263 spa codY::	 Tetr hysA::
	 Ermr
This work
AH1292 AH1263 agr::tetM 60
AH2032 AH1263 agr::tetM sigB 60, 61
AH1483 AH1263 sigB 62
AH3453 AH1263 agr::tetM codY::	 Ermr This work
AH3172 AH1263 hysA codY::	 Ermr This work
Plasmids
pET28a E. coli protein expression vector Novagen
pJB38 S. aureus gene knockout vector, Camr 31
pTet Antibiotic cassette replacement vector,
Camr Ampr
32
pSKerm-MCS E. coli-S. aureus shuttle vector, Ermr
Camr
63






pCR02 pJB38 hysA knockout vector, Camr This work




 His-tagged E. coli protein
expression vector, Kanr
This work
pCR04 pCR01 mutated CodY box, Camr Ermr This work
pCR05 pCR01 mutated CodY box, Camr Ermr This work
pCR06 pCR01 mutated CodY box, Camr Ermr This work
Ibberson et al.
4254 iai.asm.org Infection and Immunity
XhoI sites at their 5= ends, respectively. The resulting PCR product was
ligated into pET28a linearized with NheI and XhoI and electroporated
into E. coli strain ER2566 to generate strain AH2856.
To mutate the CodY binding box upstream of hysA, plasmids pCR04,
pCR05, and pCR06 were constructed using overlap PCR to engineer the
six nucleotide changes. A 5= region introducing the mutations into the
CodY box upstream of hysA was amplified using CBR35 and either
CBR83, CBR85, or CBR87. Using homologous primers to introduce the
same mutations and amplify the remainder of the hysA promoter region
and hysA, a corresponding 3= region was generated using CBR29 and
either CBR82, CBR84, or CBR86. The 5= and 3= fragments were mixed at
a ratio of 1:1 in combinations, as follows: CBR35-CBR83–CBR82-CBR29,
CBR35-CBR85–CBR84-CBR29, and CBR35-CBR87-CBR86-CBR29. Over-
lap PCR was done using the mixed fragments as a template and CBR29 and
CBR35 to amplify hysA and the promoter region containing the mutated
CodY boxes. pSKermMCS and the PCR product inserts were restriction
digested with BamHI-HF and NheI-HF and ligated using T4 DNA ligase.
The ligations were transformed into E. coli strain DH5 as previously
described. The resulting plasmids were confirmed by sequencing.
The spa mutant was generated using the same protocol for deleting
hysA described above. Flanking regions of spa (SAUSA300_0113) were
amplified with primer pair spa_delA_EcoRI and spa_delB and primer pair
spa_delC and spa_delD_SalI. The products were fused using overlap ex-
tension PCR with primers spa_delA_EcoRI and spa_delD_SalI. The re-
sulting fragment was digested with EcoRI and SalI and ligated into pJB38.
The spa deletion was confirmed by PCR with primers spa_upstream and
spa_downstream. The construct with the spa and codY double mutation
was generated by transducing the codY::	 cassette into S. aureus strain
LAC spa with bacteriophage 11. To generate strain AH3207, the pTet
marker switching plasmid was used to replace the erythromycin resistance
cassette of the codY::	 transposon insertion in S. aureus strain
AH2946 with a tetracycline resistance cassette, as described by Bose et al.
(32). This construct was then transduced by bacteriophage 11 into the
spa deletion strain that also harbored the hysA::	 transposon inser-
tion.
Protein purification. AH2856 was grown overnight at 37°C in LB
medium containing kanamycin (50 g/ml) and subcultured into 1 liter of
fresh LB medium at a ratio of 1:250. The culture was grown at 30°C to
mid-logarithmic phase, IPTG (isopropyl--D-thiogalactopyranoside)
was added to a 1 mM final concentration, and the culture was allowed to
grow for an additional 4 h. Cells were harvested by centrifugation, washed
once with water, pelleted by centrifugation, and frozen at 20°C. Cells
were mechanically lysed using a Microfluidics microfluidizer (model LV1;
Newton, MA) at 25,000 lb/in2 and running the samples through the
machine twice. Cell lysate was clarified by centrifugation for 20 min at
15,000 
 g and 4°C. Protein was purified using Fractogel His-Bind resin
(Novagen) per the manufacturer’s instructions, dialyzed into phosphate-
buffered saline (PBS), concentrated using a Millipore centrifugal filter
unit (30,000-molecular-weight cutoff), and brought to 10 mg/ml in 1

PBS. The protein suspension was frozen in 10% glycerol at 20°C until
used.
Transposon library screen. The Nebraska Transposon Mutant Li-
brary (NTML) was grown overnight in TSB in 96-well microtiter plates.
Cultures were stamped onto hyaluronic acid (HA) plates (TSB, 1% aga-
rose, 0.4 mg/ml HA, 1% [wt/vol] bovine serum albumin [BSA]), prepared
as described previously (8), and incubated at 37°C for 4 h. Acetic acid
(10%) was added to the plates to visualize zones of clearing. Plates were
scored for their hyaluronidase activity, and mutations that increased or
decreased activity were rescreened in the same manner. Mutations that
affected activity in both screens were quantitatively assessed for hyaluron-
idase activity by growing each strain overnight in TSB, subculturing to an
optical density at 600 nm (OD600) of 1.0, and dispensing the diluted cul-
ture as five aliquots (4 l) onto HA plates. After 6 h of incubation, the
plates were flooded with 10% acetic acid, and zones resulting from HA
cleavage were enumerated with a caliper.
Hyaluronidase activity assay. The hyaluronidase activity assay was
performed as previously described (28), with some modifications. Briefly,
S. aureus strains were grown overnight in TSB at 37°C with shaking, sub-
cultured 1:1,000, and grown at 37°C for the time specified below. Spent
culture medium was isolated with Spin-X filters (pore size, 0.22 m) and
frozen at 20°C until assayed. Hyaluronic acid (100 l at 1 mg/ml) was
mixed with 50 l of spent medium and allowed to react at 37°C for 15 min.
The reaction was stopped by adding 25 l of potassium tetraborate solu-
tion (0.8 M, pH 9.1), and the reaction mixture was vortexed and boiled for
3 min. In parallel, 12.5 l of spent medium was added to 31.25 l of stop
solution (0.8 mg/ml hyaluronic acid, 0.8 M potassium tetraborate, pH
9.1) at time zero, vortexed, and boiled for 3 min. The samples were dis-
pensed into a 96-well microtiter plate in quadruplicate, and freshly pre-
pared DMAB solution (10% [wt/vol] p-dimethylaminobenzaldehyde,
12.5% [vol/vol] 10 M HCl [Sigma-Aldrich], and 87.5% [vol/vol] glacial
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acetic acid [Fisher Scientific]) was added to each well. The plate was incu-
bated at 37°C for 20 min to allow the color reaction to take place. A Tecan
Infinite M200 plate reader was used to measure the absorbance at 590 nm.
Hyaluronidase specific activity is expressed as 103 
 the number of mol
N-acetylglucosamine (NAG; Sigma-Aldrich) released ml1 min1 per







 (1/OD600), where A590 represents the difference in absorbance
between the readings at 15 min and time zero for each sample, m repre-
sents the slope of the standard curve of NAG, OD600 is the optical density
of the culture when the sample was taken, 3 is the dilution factor of the
sample tested in substrate, and 1/15 is the reciprocal of the reaction time
allowed at 37°C. The assay was performed in triplicate for each condition
tested.
To determine the impact of RNAIII on hyaluronidase activity, strains
with pALC2073 or pALC2073-RNAIII were grown overnight in TSB at
37°C and were subcultured 1:1,000 into fresh TSB with anhydrotetracy-
cline (aTc) at various concentrations. Cultures were grown for 8 h, cells
were pelleted, and spent medium was filtered and assayed for activity.
Assays with limiting to rich medium. Chemically defined medium
(CDM) was made as described by Pohl et al. (33), except that the group 6
vitamin solution was replaced with nicotinamide (500 g/liter), thiamine
(500 g/liter), pantothenate (500 g/liter), and biotin (500 g/liter) (final
concentrations). Single amino acids were omitted or added in excess, as
indicated in the figure legends. The medium was buffered to pH 7.0. S.
aureus strains were grown overnight in TSB and subcultured 1:1,000 into
CDM or CDM lacking isoleucine. Bacteria were grown for 5 h, at which
point cells were pelleted, washed once with 1
 PBS, and suspended into
fresh CDM. For those cells grown in CDM lacking isoleucine, they were
then suspended in fresh CDM containing 5
 branched-chain amino ac-
ids (BCAAs; isoleucine, valine, leucine). Cells were grown in the new
medium for an additional 2 h. Growth was monitored spectrophoto-
metrically at 600 nm throughout by measuring the optical density of 100
l of culture in a 96-well microtiter plate and a Tecan infinite M200 plate
reader. Additionally, 200 l of each culture was removed at the designated
time points indicated in the figures, and spent medium was isolated using
0.22-m-pore-size Spin-X centrifuge tube filters (Costar). Spent media
were used to determine hyaluronidase activity and the presence or ab-
sence of Panton-Valentine leukocidin (PVL) (see below).
Protein immunoblot for PVL. Spent culture medium isolated from
cultures of cells grown in CDM, CDM lacking isoleucine, or CDM with
5
 BCAAs as described above (5 l for 4 h or 1 l for the other time
points) was brought to a total volume of 10 l in SDS loading buffer
containing 1% -mercaptoethanol. Proteins were resolved by PAGE us-
ing Tricine-SDS gels containing 12% polyacrylamide and 170 kV. Pro-
teins were transferred (160 mA for 1 h) onto nitrocellulose membranes
and blocked overnight at 4°C in 0.1% Tris-buffered saline containing
0.1% Tween 20 (TBST) and 5% skim milk. The membrane was probed for
PVL using Luk-S polyclonal antibody (IBT Bioservices, Gaithersburg,
MD) at 1:10,000 in TBST containing 5% skim milk for 2 h at room tem-
perature and then washed three times for 10 min each time with TBST.
Peroxidase-conjugated AffiniPure goat anti-rabbit IgG (Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) was applied at 1:20,000 in
blocking buffer at room temperature for 1 h. Membranes were washed
three times for 10 min each time with 0.1% TBST, and SuperSignal West
Pico chemiluminescent substrate (Thermo Scientific) was added to detect
proteins, followed by exposure to Classic X-ray film (Research Products
International Corporation). Bands were quantified using ImageJ soft-
ware.
Protein immunoblot for HysA. S. aureus strains AH3052, AH3134,
and AH3207 were grown overnight in TSB at 37°C with shaking at 220
rpm. The strains were subcultured at a ratio of 1:100 into fresh TSB and
grown for 8 h at 37°C with shaking at 220 rpm. Cultures were normalized
to an OD600 of 3.0 with TSB, spent media were isolated by filtration using
a 0.22-m-pore-size Millex-GS syringe filter (Millipore), concentrated
using Amicon Ultra 10,000-molecular-weight-cutoff centrifugal filters
(Millipore), and frozen at 20°C. The 10-l samples were brought to a
total volume of 15 l in SDS loading buffer containing 1% -mercapto-
ethanol, and proteins were resolved by PAGE using Tricine-SDS gels con-
taining 9% polyacrylamide and 170 kV. Proteins were transferred (160
mA for 1 h) to nitrocellulose membranes and blocked overnight at 4°C in
blocking buffer (0.1% TBST containing 5% skim milk). A rabbit poly-
clonal antibody to HysA was generated by Pacific Immunology, and the
antibody was purified as described above. HysA was probed using a dilu-
tion of 1:40,000 with the anti-HysA rabbit serum for 1 h at room temper-
ature in blocking buffer. The membrane was then washed three times for
10 min each time in 0.1% TBST. Peroxidase-conjugated AffiniPure goat
anti-rabbit IgG was applied at a 1:20,000 dilution in blocking buffer at
room temperature for 1 h. Membranes were washed three times for 10
min each time with 0.1% TBST, and SuperSignal West Pico chemilumi-
nescent substrate was added to detect proteins, followed by exposure to
Classic X-ray film.
Neutropenic murine pneumonia model. Female BALB/c mice were
purchased from the National Cancer Institute (Frederick, MD). All ani-
mals were housed under specific-pathogen-free conditions in filter-top
cages at the Walter Reed Army Institute of Research (WRAIR) Animal
Facility and provided sterile food and water ad libitum. Six- to 8-week-old
mice were injected intraperitoneally with 150 mg/kg of body weight of
cyclophosphamide (Baxter) 4 days prior to infection and 100 mg/kg of
cyclophosphamide 1 day prior to infection, as previously described (34).
Mice were anesthetized with isoflurane and infected intranasally with
1.0 
 107 CFU of S. aureus suspended in 25 l of PBS. At 48 h postinfec-
tion, the mice were euthanized and lungs were extracted, homogenized,
and serially diluted before suspensions of lung tissue were plated onto
TSA. The CFU were enumerated to assess the bacterial burden. For sur-
vival studies, infected mice were monitored twice a day for signs of mor-
bidity. Following sacrifice, paraffin-embedded lung tissue samples from
infected and uninfected mice were sectioned and stained with hematoxy-
lin-eosin (H&E). All procedures were performed in accordance with a
protocol approved by the WRAIR Institutional Animal Care and Use
Committee (protocol number IB02-10). All animal research was con-
ducted in compliance with the Animal Welfare Act and other federal
statutes and regulations relating to animals and experiments involving
animals and adheres to the principles stated in the Guide for the Care and
Use of Laboratory Animals (35).
Immunohistochemistry. The lungs of PBS-treated and infected mice
were harvested at 48 h postinfection, fixed in 4.0% paraformaldehyde, and
cut into 5-m sections. As a control, uninfected lung tissue samples were
pretreated with 100 turbidity reducing units (TRU) of Streptomyces hya-
lurolyticus hyaluronidase (Sigma) for 2 h at 60°C (36). Hyaluronic acid
was labeled as previously described (37). Briefly, samples were incubated
in 0.2% BSA for 2 h at 4°C to block nonspecific binding. Following incu-
bation, samples were treated with 2 g/ml of biotinylated hyaluronic acid
binding protein (EMD Biosciences) for 16 h at 4°C. Fluorescein isothio-
cyanate-conjugated streptavidin (Invitrogen) was used to visualize hyal-
uronic acid. The presence of hyaluronic acid in lung sections was quanti-
fied by measuring the mean fluorescent intensity of 40 fields per section.
Images were acquired with an Olympus AX80 microscope and analyzed
with Image Pro (version 7.0) software.
Statistical analysis. The statistical significance of all data was analyzed
using the Student t test with GraphPad Prism (version 6) software
(GraphPad, La Jolla, CA), except for data from survival studies. Data from
the survival studies were analyzed by the Mantel-Cox test (P  0.0022).
RESULTS
The gene encoding hyaluronidase (hysA) is conserved across all S.
aureus clonal lineages (8), and only one hyaluronidase is carried
by the genome of a community-associated MRSA (CA-MRSA)
USA300 strain (38). The hysA gene (SAUSA300_2161) is located
near a number of genes of unknown function and is transcribed by
itself in the opposite direction of neighboring genes (Fig. 1A). To
Ibberson et al.
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begin our studies on hysA, we created a markerless deletion con-
struct in strain AH1263 (39), an erythromycin-sensitive version of
the USA300 isolate LAC (here called LAC wild type [LAC-WT]).
The hysA knockout mutant was confirmed by PCR and a lack of
enzymatic cleavage of HA by an agar plate assay (Fig. 1B). We also
verified the absence of hyaluronidase activity in the knockout mu-
tant using a quantitative, spectrophotometric assay (Fig. 1C). The
HysA activity was complemented to LAC-WT levels by providing
hysA on a plasmid (Fig. 1), demonstrating that the phenotype was
due to the mutant construction and not secondary or polar effects.
The regulation of hysA has received only limited attention,
although there are reports for the potential involvement of global
regulators sarA and agr (28, 29). To identify genetic loci that con-
tribute to hysA regulation, we screened 1,952 mutants from the
Nebraska Transposon Mutant Library (NTML) (40) for hyal-
uronidase activity using an HA plate assay. Screening of the
NTML resulted in the identification of eight bursa aurealis trans-
poson insertions that significantly altered hyaluronidase activity.
To determine the relative extent to which each mutation affected
activity, five replicates of each mutant were spotted on HA plates
and the zone size was enumerated with a caliper (Fig. 2A). NTML
WT strain JE2 had an average zone size of 1.01  0.02 cm, while a
mutation in hysA resulted in no detectable zone of clearing. Mul-
tiple strains with insertions in the sigma factor B operon (sigB,
rsbU, and rsbW) and strains with insertions in sarA, hslU, and codY
had elevated hyaluronidase activity. Interestingly, insertion into
the putative deaminase, SAUSA300_0543, gave a reduced zone of
clearing of HA (0.76  0.03 cm) and was the only mutation in the
library besides hysA to cause the strain to have a zone size smaller
than the WT zone size.
To quantitatively measure the effect of the identified trans-
poson insertions on hyaluronidase activity, we performed a spec-
trophotometric specific activity assay on spent medium of 8-h
cultures (Fig. 2B). In support of the results of the HA plate assay,
the codY transposon mutant was found to have activity that was
increased 12-fold compared to that of the WT. Additionally, mul-
tiple insertions in the sigB operon, as well as one in hslU, increased
the activity approximately 3-fold, and an insertion in sarA resulted
in a 10-fold increase. The mutant with the transposon insertion in
SAUSA300_0543 had one-third of the activity of the WT (Fig. 2B),
similar to the reduction in activity observed in the HA plate assay.
As expected, no activity by the hysA transposon mutant was ob-
served in this assay.
Despite previous reports of agr quorum-sensing involvement
in hysA regulation (28), we did not find any insertions in the agr
locus that significantly altered hyaluronidase activity in our
screen. We hypothesized that this was perhaps due to the fact that
S. aureus strain 8325-4, which has a known mutation in rsbU that
results in a defect in SigB activity, was used in the previous study.
As shown in Fig. 2, we found multiple mutations in the sigB
operon, including a mutation in rsbU, that increase hyaluronidase
activity. Thus, a role for agr could be masked in the USA300 back-
ground that has an intact rsbU gene. To investigate this question,
we shifted our studies to the USA300 LAC (LAC-WT) back-
ground, and we quantified HysA activity in LAC-WT as well as the
agr and sigB single mutant and agr sigB double mutant strains. We
found that HysA activity was unchanged in an agr mutant and
increased significantly in a sigB mutant. Comparing the sigB agr
double mutant to the sigB mutant (Fig. 3A), there was a significant
decrease in activity when agr was deactivated. This observation is
in agreement with published reports (28), and we also made sim-
ilar observations in the USA400 MW2 background (data not
shown), indicating that this effect occurs across multiple S. aureus
strain types.
CodY is reported to regulate the agr system (41, 42), and we
hypothesized that some hysA regulation might be occurring indi-
rectly through the known CodY-agr interactions. To address this
question, we initially confirmed that the effect of CodY was con-
sistent in the LAC background by crossing the transposon inser-
tion into LAC-WT, and we observed that HysA activity increased
16-fold in the codY mutant over that in LAC-WT (data not
shown). Next, we quantified HysA activity in LAC-WT, as well as
in the agr and codY single mutant and agr codY double mutant
strains (Fig. 3B). As anticipated, HysA activity was unchanged in
an agr mutant and increased in a codY mutant. However, HysA
activity was significantly decreased in the agr codY double mutant
compared to that in the codY mutant (Fig. 3B). We speculated that
the unnaturally high levels of RNAIII in the codY mutant could be
distorting HysA production. To test this question, we transformed
USA300 WT with a plasmid that expresses RNAIII under the con-
trol of a tetracycline-inducible promoter. In the absence of the
inducer, there was essentially no difference in HysA activity be-
FIG 1 Generation and initial characterization of the CA-MRSA USA300 hysA mutant and complemented strains. (A) Location of hysA on the CA-MRSA
USA300 LAC chromosome. Numbers indicate SAUSA300 locus numbers. The hysA gene is surrounded by genes with unknown function and is transcribed by
itself on the chromosome. (B and C) HA plate and hyaluronidase (HL) specific activity assays of LAC-WT, LAC hysA, and complemented (pHysA) strains. As
shown, HysA activity is abolished for the hysA mutant and restored to WT levels when it is complemented in both assays.
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tween this strain and an empty vector control (Fig. 3C). However,
HysA activity increased with the induction of RNAIII expression
compared to the activity of the control (Fig. 3C). Collectively,
these data lead us to suggest the model depicted in Fig. 3D for
CodY and agr-mediated regulation of HysA.
In considering the regulatory model (Fig. 3D), it still remained
possible that CodY directly regulated hysA gene expression. The
CodY regulon has been investigated previously (41–43), and hysA
was not identified as a target in any of these studies. We inspected
the sequence upstream of hysA for the presence of the previously
published CodY consensus binding box (41), and we found a well-
conserved CodY binding box 202 bp upstream of the putative
translational start site (Fig. 4A), with one nucleic acid change from
a cytosine to a thymine being found in the region between the
inverted repeats. The presence of this box led us to predict that
CodY may interact with the hysA putative promoter region. To
confirm that we were not being misled by the results of the hyal-
uronidase activity assays, we tested to see if the HysA protein levels
increased accordingly in a codY mutant. We used an antibody to
HysA that was developed and found by immunoblotting that en-
zyme levels were increased in a codY mutant compared to those in
the WT strain (Fig. 4B). To eliminate background binding in the
immunoblot, protein A was inactivated in each of these strains.
The band corresponding to HysA was not detected in a codY hysA
double mutant, demonstrating that the antibody was specific and
suggesting that the increase in hyaluronidase activity is due to
elevated HysA levels. Also of note, HysA was not stable in spent
medium, and we frequently observed lower-molecular-weight
breakdown products by immunoblotting (Fig. 4B).
To assess whether CodY was acting to directly regulate hysA, we
constructed plasmids with CodY binding box mutations in the
hysA promoter region (Fig. 4C). As our testing system, we used the
LAC hysA mutant with plasmid pHysA, which complements hy-
aluronidase activity to nearly WT levels (Fig. 1C). Using pHysA as
a backbone, we introduced five to six nucleotide substitutions
from the consensus sequence into the CodY box, and these were
based on previous studies in Bacillus subtilis, where this number of
changes was sufficient to disrupt CodY-based repression (44).
These constructs were tested by transforming them into the LAC
hysA mutant or hysA codY double mutant and measuring HysA
activity from plasmid expression. We first introduced A-to-C and
T-to-C changes into the first half site of the box in constructs
FIG 2 Transposon mutagenesis library screen for altered HysA activity. (A) Summary of results of screen for HysA activity on HA agarose plates. Values of HysA
activity are reported as diameters (cm) of zones of clearing, measured with a caliper, and represent the means  standard deviations of five technical replicates
for each strain plated on HA agarose. Pictures are representative images of each strain. (B) Hyaluronidase specific activity assay of strains containing mutations
that significantly altered HysA activity on HA agarose plates. The data are presented as the fold changes compared to the activity of USA300 WT strain JE2. Values
represent the means and standard deviations of four technical replications for three independent biological determinations. Statistical significance (****, P 
0.0001) was determined by Student’s t test.
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pCR04 and pCR05 (Fig. 4C). In testing these constructs, the
CodY-based repression of HysA activity was reduced markedly to
approximately 2-fold (Fig. 4D). We made additional, indepen-
dent nucleotide changes in the second box half site in construct
pCR06 (Fig. 4C), and CodY-based repression of HysA activity was
completely eliminated (Fig. 4D). These results provide strong sup-
port for the suggestion that CodY directly regulates hysA expres-
sion through binding to the box identified in the promoter region.
Finally, we took advantage of the CodY response to the avail-
ability of branched-chain amino acids (BCAAs) to test the possi-
bility that CodY represses HysA production in response to envi-
ronmental changes. CodY gains a high affinity for target
promoters when BCAAs are available, leading to repression of its
targets. When BCAAs are limiting, such as when cells are in sta-
tionary phase or under starvation, CodY loses this affinity, result-
ing in relieved repression of CodY targets (45, 46). We grew
LAC-WT in chemically defined medium (CDM) lacking isoleu-
cine or in CDM with standard levels of BCAAs until the cells began
to enter stationary phase (Fig. 5A). If hysA is under CodY control,
we would anticipate increased HysA activity in the cells grown
without isoleucine compared to that in cells grown in CDM with
standard levels of BCAAs. In support of this hypothesis, there was
a more than 2.5-fold increase in hyaluronidase activity when
BCAAs were limiting compared to that when bacteria were grown
in CDM at both 4 and 5 h (Fig. 5B).
We also tested the impact of high levels of BCAAs on CodY
repression. The cells grown in medium lacking isoleucine were
switched to medium that contained excess BCAAs. If hysA is un-
der CodY control, we would anticipate that the excess BCAAs
would bind to CodY and repress expression. As predicted, when
BCAAs were supplied in excess, HysA production dropped over
5-fold compared to that in cells grown in CDM (Fig. 5B). These
activity changes were not due to differences in growth (Fig. 5A). As
a control, samples were taken from each time point and immuno-
blot assays for Panton-Valentine leukocidin (PVL) (Fig. 5C and
D), which is known to be regulated by CodY in USA300 lineages,
were performed (47). The trends in PVL production mirrored
those of HysA production under all the conditions tested, suggest-
ing that they are regulated in a similar manner.
To determine whether HysA is required for virulence, neutro-
penic BALB/c mice were infected intranasally with 1 
 107 CFU of
either LAC-WT or the hysA mutant. After 4 days of infection,
80% of mice infected with LAC-WT succumbed to infection,
which is in striking contrast to the death of only 20% of mice
infected with the hysA mutant (Fig. 6A). At 48 h postinfection, a
4-log-unit reduction in the bacterial burden was observed in the
lungs of mice infected with the hysA mutant compared to the
bacterial burden in the lungs of mice infected with LAC-WT (Fig.
6B), suggesting that the virulence defect is likely caused by an
inability of the mutant to replicate in the lungs of infected mice.
The hyaluronidase activity of multiple Gram-positive patho-
gens has been shown to cause severe tissue damage in vivo (12, 13,
FIG 3 Role of the agr system in hysA gene regulation. Cultures of various LAC strains were grown for 8 h, spent medium was prepared, and the hyaluronidase
specific activity in each sample was measured. (A) To assess the agr and SigB interaction, activity was measured in the WT, agr and sigB single mutant, and agr
sigB double mutant strains and plotted. (B) To assess the agr and CodY interaction, activity was measured in the WT, agr and codY single mutant, and codY agr
double mutant strains. For panels A and B, statistical significance (****, P  0.0001) was determined by Student’s t test. (C) Hyaluronidase specific activity for
the WT containing the empty vector (black bars) or RNAIII under the control of a tetracycline-inducible promoter (gray bars). Student’s t test was used to
determine statistical significance (**, P  0.01; ****, P  0.0001). (D) Model for SigB and CodY regulation of HysA through the agr system.
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28). Therefore, we investigated whether the loss of virulence of the
hysA mutant strain was associated with reduced tissue damage in
the lung. Histological analysis showed that the lungs of mice in-
fected with the hysA mutant exhibited less pathology and influx
of alveolar macrophages than the lungs of LAC-WT-infected mice
(Fig. 6C). To determine whether hyaluronidase activity contrib-
uted to the virulence of S. aureus in vivo, HA was fluorescently
labeled and quantified in the lungs of infected mice. There was a
significant increase in the amount of HA (P  0.0001) present in
the lungs of hysA mutant-infected mice compared with the
amount present in the lungs of LAC-WT-infected mice (Fig. 7A
and B). In fact, the level of HA present in the lungs of wild-type-
FIG 4 The CodY binding box is required for hysA regulation. (A) Location of the putative CodY binding box in the hysA promoter region. An alignment of the
consensus CodY binding box and the proposed hysA box is shown. (B) Immunoblotting for HysA performed with a LAC-WT strain. Spent medium was
concentrated 20- or 50-fold from the WT and the codY and codY hysA mutant strains, as indicated, and immunoblotted for HysA. In each strain, a spa deletion
was engineered to remove background antibody binding. (C) Mutations generated in the CodY box in plasmids pCR04, pCR05, and pCR06. (D) Hyaluronidase
specific activity assay at 8 h for the WT (LAC hysA with one of the indicated plasmid constructs) or a codY mutant (the LAC hysA codY double mutant with
one of the indicated plasmid constructs) containing the pHysA, pCR04, pCR05, or pCR06 construct. Statistical analysis was performed using a Student’s t test
(****, P  0.0001).
FIG 5 Effect of nutrient availability on hysA regulation. (A) Growth curve of LAC-WT grown in CDM or in CDM lacking isoleucine for the first 5 h. Cells were
harvested by centrifugation, washed 1 time in PBS, and suspended in either fresh CDM or CDM containing 5
 BCAAs. Arrows, times when samples were taken
or where medium was switched, as indicated. (B) Hyaluronidase specific activity of samples taken at the time points indicated in panel A. Statistical analysis was
performed using Student’s t test (****, P  0.0001). (C) Immunoblot for the LukS subunit of PVL at the time points indicated in panel A. (D) Quantification of
LukS immunoblot using ImageJ software. post, samples taken at time points after the medium switch.
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infected mice was similar to that found in the lungs of mice treated
with purified hyaluronidase from Streptomyces hyalurolyticus (Fig.
7C). Taken together, these findings show that hysA is an important
determinant as a cause of S. aureus infection.
DISCUSSION
Hyaluronidases are thought to act as spreading factors, allowing
dissemination of pathogens throughout mammalian tissue during
infection (9). In fact, the earliest studies on spreading factors de-
scribed them as agents that increase lesion size when combined
with various bacterial and viral pathogens (17, 21). In this report,
we investigated the regulation and in vivo function of HysA during
S. aureus infection using a CA-MRSA USA300 strain, and we
found that HysA is indeed an important factor for causing an
infection.
Through our screen of the NTML, we identified eight muta-
tions that significantly altered HysA activity, including a mutation
in sarA, multiple mutations in the sigB operon, and a mutation in
an uncharacterized nucleoside deaminase encoded by the
SAUSA300_0543 gene. The deaminase was the only target identi-
fied that is required for the full expression of HysA. Surprisingly,
we did not identify mutations in the agr locus during the screen,
although it was reported that agr is required for HysA production
(28). Considering that the previous studies were done with a strain
with a natural mutation in rsbU, which is known to mimic a sigB
mutation and elevate agr function (48), we investigated this ques-
tion. When an agr deletion was introduced into a sigB mutant, we
observed a drop in HysA activity (Fig. 3A), supporting the find-
ings of the previous studies. Taken together, when the agr system
is hyperactivated, HysA levels increase, and by removing the agr
locus, these levels drop, which supports the previously identified
agr-dependent regulation. We speculated that this agr role oc-
curred only at unnaturally high levels of RNAIII, and we con-
firmed this by expressing RNAIII from a plasmid and boosting
HysA output. Thus, agr has a role in HysA production, but it
seems to be important only in situations where RNAIII is elevated
beyond normal WT levels.
Interestingly, our screen of the NTML revealed that a mutation
in the global regulator CodY resulted in increased HysA activity.
CodY responds to intracellular concentrations of branched-chain
amino acids in S. aureus to control target gene expression (33, 41,
42, 45). We initially speculated that the CodY regulation might be
indirect through the agr system, and indeed, the introduction of
an agr deletion reduced the level of HysA production in a codY
mutant (Fig. 3B). However, we observed that the hysA promoter
region had a nearly perfect CodY binding box (Fig. 4A), and im-
portantly, nucleotide changes to the conserved positions of the
box eliminated CodY-based repression (Fig. 4C and D). Thus,
there are indirect and direct mechanisms of CodY-dependent reg-
ulation occurring to coordinate HysA production in S. aureus.
CodY-dependent regulation suggests that HysA has a potential
nutrient-scavenging function. HA is a major component of the
viscous substance produced by connective tissues, and it acts as a
host defense mechanism by creating a protective barrier that im-
pedes the penetration of bacteria and bacterial products into
deeper tissues (49). Sequestration of essential nutrients, such as
FIG 6 HysA is required for USA300 virulence. Mice were intranasally inoculated with 1.0 
 107 CFU of either LAC-WT, its hysA mutant strain, or PBS. (A)
Mice (n  27) were monitored daily for signs of morbidity and mortality. **, P  0.0022, Mantel-Cox test. (B) Groups of mice (n  21) were euthanized after
48 h, and the bacterial burden in the lungs was quantified by CFU enumeration. **, P  0.0095. (C) Histopathology of the lungs from mice treated with PBS or
infected with either LAC-WT or the hysA mutant. Black arrowheads, areas shown in the enlarged images in the insets. Data are representative of those from three
independent experiments.
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iron (50) and tryptophan (51), is another mechanism of bacterial
infection prevention that works through the generation of nutri-
ent-limited environments. Bacterial pathogens can rapidly adapt
to these hostile situations by regulating the expression of genes
important for virulence and metabolism (52), and our findings
suggest that S. aureus uses CodY to regulate HysA in this manner.
HA can be broken down by hyaluronidases produced by a variety
of bacterial pathogens, such as Streptococcus pyogenes, Streptococ-
cus pneumoniae, and Mycobacterium tuberculosis (9), and metab-
olized as a source of carbon (53–55). At this time, it has not been
clearly demonstrated that S. aureus can use HA as a carbon source
in vivo or whether HysA is involved in this growth mechanism.
Both questions are in need of further examination. However, it is
possible that the reduction in bacterial burden in a hysA mutant
during pulmonary (Fig. 6B) and soft tissue (28) infections can be
explained by an inability of S. aureus to utilize an alternative car-
bon source under nutrition-limited conditions in vivo.
This finding is consistent with the findings of previous work
showing that CodY regulates other virulence factors to act as a link
between metabolism and virulence (33). For example, the hemo-
lysins ( and ), as well as the secreted proteases SspA and SspB,
have been shown to be regulated directly by CodY. HysA was
required for the breakdown of HA in vivo, and this correlated with
a loss of structural integrity and enhanced necrosis of pulmonary
tissues, allowing the pathogen access to deeper tissues. In addition
to HysA, S. aureus possesses other mechanisms for penetrating the
host. One example is a secreted cysteine protease, staphopain A,
which is able to induce vascular leakage during a guinea pig infec-
tion (56), and this effect can be augmented by the addition of
another secreted cysteine protease, staphopain B. Additionally,
lipases have been observed to enhance S. aureus tissue penetration
(57). Taken together these results indicate that HysA is part of a
class of S. aureus secreted proteins that act in a coordinated fash-
ion as spreading factors by breaking down host tissues to facilitate
bacterial dissemination (22). Interestingly, the target for each en-
zyme differs, despite the functional redundancy of these proteins.
Considering the dynamic range of infections caused by S. aureus,
these findings lead us to speculate that these spreading factors may
FIG 7 HysA is required for the breakdown of hyaluronic acid in vivo. (A and B) Micrographs of immunofluorescently labeled HA in the lungs of mice inoculated
with 1.0 
 107 CFU of either strain LAC-WT or its hysA mutant strain. (C) The mean fluorescence intensity was quantified for each sample (40 fields per
section). A sample treated with hyaluronidase from Streptomyces hyalurolyticus (Strep Hys) was also included as a control. NS, not significant; ****, P  0.0001.
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be a part of a fine-tuned virulence mechanism utilized by this
pathogen to nonspecifically break down host barriers and pro-
mote dissemination from any site of infection.
Our studies give new insights into the regulation and role of the
S. aureus virulence factor HysA. This work identified an important
link between metabolism and virulence by illustrating a relation-
ship between the metabolic regulator CodY and the virulence fac-
tor HysA. By therapeutic targeting of HysA and other spreading
factors, it might be possible to prevent localized infections from
evolving into more complicated, systemic disease.
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